Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    Drug Interactions a Danger for Patients Taking Antipsychotics: Presented at APA - (DGDispatch)
    Monthly Injectable Atypical Antipsychotic Reduces Schizophrenia Relapse Rate: Presented at APA - (DGDispatch)
    Long-Acting Injectable Risperidone Ramps Up Compliance for Schizophrenia Patients: Presented at APA - (DGDispatch)
    FDA Approves Aripiprazole as Adjunctive to Lithium or Valproate in Adults With Bipolar 1 Disorder - (DGNews)
    Aripiprazole Receives Expanded Paediatric Indications for Bipolar I Disorder and Schizophrenia - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
  • Multimodal Management Emphasized in Early-Onset Schizophrenia
  • Improving Functional Outcomes: Assessment and Management of Cognitive Dysfunction in Patients with Schizophrenia

    Webcasts/CME archive

     Recent cases - Schizophrenia
      A Familial Concurrence of Schizophrenia and Gaucher's Disease
      Necrotising Colitis Related to Clozapine? A Rare but Life Threatening Side Effect
      Case Report: Psychosis in an Adolescent with Sickle Cell Disease
      Case Report: Rapidly Fatal Bowel Ischaemia on Clozapine Treatment
      Excessive Weight Gain after Remission of Depression in a Schizophrenic Patient Treated with Risperidone: Case Report

      Cases archive
        




      my personal edition > schizophrenia > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Mirtazapine Plus Clozapine Appears to Improve Negative Symptoms of Schizophrenia

      A DGReview of :"The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study"
      International Clinical Psychopharmacology

      04/21/2004
      By Mary Beth Nierengarten


      The addition of mirtazapine to clozapine for treatment of schizophrenia appears to improve negative symptoms associated with schizophrenia, report Italian researchers.

      Developing effective treatment of negative symptoms associated with schizophrenia is a primary treatment goal, with recent studies suggesting an efficacy with dual action compounds, the noradrenergic and specific serotonergic antidepressants (NaSSa).

      To test the safety and efficacy of mirtazapine, the first drug of this new class of NaSSa, in this setting, Rocco Zoccali, MD, Psychiatric and Anaesthesiological Sciences, University of Messina, and colleagues conducted an 8-week, double-blind, placebo-controlled trial in which 12 outpatients diagnosed with schizophrenia were randomised to mirtazapine (30 mg/day) and 12 to placebo after at least 1 year of clozapine monotherapy (150-650 mg/day). All patients remained on clozapine throughout the study. Patients were included in the study because they exhibited negative symptoms that persisted despite adequate clozapine treatment.

      Efficacy was assessed using the Brief Psychiatric Rating Scale (BPRS) administered at baseline and at 8 weeks, as well as the Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS) administered at baseline and at the end of weeks 2, 4, and 8.

      Of the 24 patients, 10 from each group were available for analysis. At 8 weeks, patients in the mirtazapine group had significantly lower SANS scores than those in the placebo group (39.0 vs. 51.0, respectively; P < .01) and had significant improvement in the SANS subscales avolition/apathy (6.3 vs. 9.7, respectively; P < .05) and anhedonia/asociality (8.0 vs. 10.6, respectively; P < .05). These significant improvements in negative symptoms with mirtazapine were also significant after 4 weeks of treatment compared to baseline values (P < .01). Mirtazapine also showed superiority over placebo in reducing negative symptoms based on the total BPRS score at 8 weeks (25.4 vs. 44.7, respectively; P < .01). Positive symptoms as measured by SAPS were not changed in either group at the end of the 8 week study period.

      Overall, mirtazapine was well tolerated with only mild and transient drowsiness seen in 3 patients and weight gain in 2 patients.

      Despite limitations of this study that included small sample size, limited trial duration, and inter-individual variability in clinical response, the authors conclude that "the addition of mirtazapine to clozapine treatment is well tolerated and may be proposed as an useful therapeutic strategy to improve negative symptoms in chronic schizophrenic patients."

      Int Clin Psychopharmacol 2004 Mar;19:2:71-6. "The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send